News & Events
Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 3, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will participate in a panel discussion at the Cowen 42nd Annual…
Australian collaborative research into gut microbiome-autism link featured in GenomeWeb (opens in a new tab)
Researchers from The University of Queensland & Mater Research will present their findings alongside Microba’s Dr David Wood in a webinar on examining the microbiome for new discoveries in human health. In the largest study in the field to date, researchers used Microba’s metagenomic analysis and bioinformatic expertis…
Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (opens in a new tab)
– SER-109 Phase 3 study results in recurrent C. difficile infection published in New England Journal of Medicine – Biologics License Application (BLA) filing for SER-109 anticipated in mid-2022 – – Investor webcast highlighted the broad potential of microbiome therapeutics as a novel approach for…
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 22, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 1, 2022 at 8:30 a.m. ET to discuss fourth quarter and full year 2021…
Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 22, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will present at the Chardan Metagenomics and Microbiome Medicines…
Year-End Report October – December 2021 (opens in a new tab)
The post Year-End Report October – December 2021 appeared first on Genetic Analysis.…
IMD – Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany (opens in a new tab)
The post IMD – Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany appeared first on Genetic Analysis.…
Alveolus Bio’s Founder, Dr. Vivek Lal, to Present at BIO CEO & Investor Conference (opens in a new tab)
The post Alveolus Bio’s Founder, Dr. Vivek Lal, to Present at BIO CEO & Investor Conference appeared first on Alveolus Bio .…
Arc Bio Joins Microbiome Therapeutics Innovation Group (opens in a new tab)
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer (opens in a new tab)
Cloghessy to focus on supporting an inclusive culture and the Company’s continued growth trajectory CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 8, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Paula Cloghessy , SPHR, SHRM-SCP, has…
The Microbiome Test from Genetic Analysis AS launched on a new technology platform, GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system (opens in a new tab)
The post The Microbiome Test from Genetic Analysis AS launched on a new technology platform, GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system appeared first on Genetic Analysis.…
Genetic Analysis AS (GA) reports first commercial sales of the enhanced GA-map® Dysbiosis Test version 2 (opens in a new tab)
The post Genetic Analysis AS (GA) reports first commercial sales of the enhanced GA-map® Dysbiosis Test version 2 appeared first on Genetic Analysis.…
Microba to present therapeutic discovery progress at Microbiome Movement – Drug Development summit (opens in a new tab)
Microba Life Sciences, a precision microbiome science company, will showcase its Therapeutic Platform and Discovery Platform for the identification of novel microbial signatures at annual Europe summit. The event brings together researchers from the biopharmaceutical industry to discuss the latest scientific discoverie…
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jan. 24, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host a webcast investor event on Monday, January 31, 2022 , from 8:30 a.m. to 10:00 a.m. ET .…
New England Journal of Medicine Publishes Data from ECOSPOR III Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection (opens in a new tab)
– SER-109 achieved statistically significant and clinically meaningful improvements in key primary and secondary efficacy measures compared with placebo – – SER-109 was well tolerated, with a safety profile comparable to placebo – – Company expects to finalize Biologics License Application (BLA)…
Genetic Analysis AS and Thalys Medical Technology Group enter Microbiome Laboratory Developed Test (LDT) agreement for the Chinese market (opens in a new tab)
The post Genetic Analysis AS and Thalys Medical Technology Group enter Microbiome Laboratory Developed Test (LDT) agreement for the Chinese market appeared first on Genetic Analysis.…
Alveolus Bio to Present at Biotech Showcase 2022 (opens in a new tab)
The post Alveolus Bio to Present at Biotech Showcase 2022 appeared first on Alveolus Bio .…
Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration (opens in a new tab)
Ken Blount1*, Courtney Jones1, Dana Walsh1, Carlos Gonzalez2 and William D. Shannon21Rebiotix Inc., a Ferring Company, Roseville, MN, United States, 2BioRankings LLC, St. Louis, MO, United States Background The human gut microbiota are important to health and wellness, and disrupted microbiota homeostasis, or “dysbiosi…
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jan. 4, 2022– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:15 a.m. ET .…
Genetic Analysis summarizes a successful year (opens in a new tab)
The post Genetic Analysis summarizes a successful year appeared first on Genetic Analysis.…